Monday, 7 February 2011
AstraZeneca today announced the appointment of John Yee, MD, MPH to the newly created role of vice president and U.S. head medical officer, responsible for overseeing all U.S. business medical affairs activities.
Yee has been at Genzyme since 2003, where he held various medical affairs leadership roles with key responsibilities including disease registries, medical education, scientific symposia and investigator-sponsored research.
“John’s breadth and depth of clinical and industry experience are a great fit with our U.S. business strategy,” said Rich Fante, president, AstraZeneca U.S. and CEO North America. “He shares our deep devotion to making the most meaningful difference to health through great medicines that provide important benefits to patients.”
As vice president of Global Medical Affairs at Genzyme, Yee built and led the Global, U.S., and European teams for the company’s flagship Personalized Genetic Health business unit. Most recently, he served as vice president and global head of Evidence-Based Medicine and Health Outcomes Research and as the founding leader of Genzyme’s Evidence-Based Medicine Center of Excellence.
In addition to his roles at Genzyme, Yee has served in leadership roles at a major academic medical center, at health care technology start-up companies and as a clinical research consultant to pharmaceutical, biotechnology and medical device companies.
Prior to joining industry, Yee served as a faculty member at Harvard Medical School and at Children’s Hospital Boston. He is a graduate of Harvard College, and earned his medical degree from Harvard Medical School in addition to a master’s degree in public health from the Harvard School of Public Health. He completed his residency and fellowship training at Children’s Hospital Boston.
NOTES TO EDITORS:
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of $32.8 billion in 2009. In the United States, AstraZeneca is a $14.8 billion healthcare business.
For more information about AstraZeneca in the US or our AZ&Me™ Prescription Savings programs, please visit: www.astrazeneca-us.com or call 1-800-AZandMe (292-6363).
Katie Lubenow, AstraZeneca: 302-885-9960